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Conclusions Moderate preoperative TR is a significant risk 
factor for severe postoperative TR in patients undergoing 
mitral valve surgery. The aggressive application of TVR 
can prevent severe postoperative TR; however, tricuspid 
annular dilatation might not be a good indicator for TVR.
Keywords Mitral valve · Surgery · Tricuspid 
regurgitation · Tricuspid valve repair · Tricuspid annular 
dilatation
Introduction
Severe tricuspid regurgitation (TR) is associated with a 
reduction in exercise capacity and a poor functional out-
come [1, 2]. Patients with severe TR who undergo mitral 
valve surgery should undergo concomitant tricuspid valve 
repair (TVR) because TR does not usually resolve if only 
the mitral valve is repaired. However, it remains unclear 
whether patients with moderate or mild TR should undergo 
TVR at the time of mitral valve surgery. Some patients 
with moderate or mild preoperative TR develop severe late 
postoperative TR [3–9]. Thus, some authors recommend 
that such patients should undergo prophylactic TVR at the 
time of mitral valve surgery [3, 6–10]. The recent guide-
lines for the management of valvular heart disease from the 
European Society of Cardiology/European Association for 
Cardio-thoracic Surgery [11] and the American College of 
Cardiology/American Heart Association [12] recommend 
that concomitant TVR should be considered in patients 
with tricuspid annular dilatation, prior evidence of right 
heart failure, or pulmonary hypertension (recommendation 
class IIa or IIb).
We have seen a considerable number of patients with 
insignificant preoperative TR who developed severe TR 
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after mitral valve surgery. Since 1998, we have there-
fore performed TVR (tricuspid annuloplasty using a flex-
ible prosthetic ring) more aggressively for patients with a 
dilated tricuspid annulus, regardless of the severity of TR. 
In this study, we retrospectively studied the risk factors for 
the development of severe TR in patients without severe 
preoperative TR dating back to the period before we began 
aggressively applying TVR. We also studied the effects of 
prophylactic TVR on severe postoperative TR. Finally, we 
assessed the validity of our indication (i.e., tricuspid annu-
lar dilatation) for TVR in patients without severe TR who 
underwent mitral valve surgery.
Methods
Study population
Between 1987 and 2006, 237 patients underwent mitral 
valve surgery at Osaka General Medical Center (Fig. 1). 
We excluded cases involving severe (grade 3+) preopera-
tive TR (n = 81), patients in whom the tricuspid annular 
diameter (TAD) was not measured (n = 9), patients who 
died within 1 year after surgery (including six hospital 
deaths) (n = 9), patients with the postoperative recurrence 
of significant mitral valve disease or periprosthetic valvular 
leakage (n = 7), patients who were lost to follow-up within 
1 year (n = 4), and patients with organic (rheumatic) tricus-
pid valve disease (n = 2). The remaining 125 patients were 
included in this study. The study protocol was approved by 
the institutional ethics committee of Osaka General Medi-
cal Center (Approval number: 27-S1901).
In 1998, we changed our policy regarding TVR in 
patients undergoing mitral valve surgery. Before 1998 
(early period), we only repaired the tricuspid valve in 
patients with severe TR. Beginning in 1998 (late period), 
we considered patients with a TAD of ≥35 mm as candi-
dates for concomitant TVR, regardless of the presence or 
severity of TR. Thus, none of the 54 patients in the early 
period of this study underwent TVR, and 52 of the 71 
(73 %) patients in the late period underwent TVR. Seven 
late-period patients were not treated according to the 
above-mentioned policy at the discretion of the surgeon; 
these included 6 of the 57 patients with a TAD of ≥35 mm 
who did not undergo TVR and one patient with a TAD 
of <35 mm (28 mm) who underwent TVR.
The characteristics of the 125 patients (early period, 
n = 54; late period, n = 71) are shown in Table 1. Because 
there was a time difference between the early and late peri-
ods, the characteristics of the two groups, such as age, the 
rate of rheumatic disease, and the rate of atrial fibrillation 
or pulmonary hypertension (defined by a mean pulmonary 
arterial pressure of ≥25 mmHg on cardiac catheterization 
or preoperative echocardiography), were different from 
each other. The mitral valve was replaced in the major-
ity of patients in this study, and this is conspicuous in the 
early period, where all but one underwent mitral valve 
replacement.
The severity of preoperative TR was classified as none 
(grade 0) in five patients, mild (grade 1+) in 82, and mod-
erate (grade 2+) in 38. The mean (standard deviation [SD]) 
TAD measured in late diastole was 36.5 (5.2) mm and the 
mean (SD) indexed TAD (TAD/body surface area) was 
24.1 (3.8) mm/m2.
Surgical procedure
Surgery was performed under moderate hypothermia and 
cardiopulmonary bypass. Mitral valve surgery and con-
comitant procedures were performed with aortic cross-
clamping and either repeated antegrade or antegrade and 
retrograde cold cardioplegia. Only one patient in the early 
period underwent left atrial plication for a huge left atrium.
To repair the tricuspid valve, tricuspid annuloplasty 
using a flexible ring was performed in 52 patients (all in 
the late period). A Duran-Medtronic ring (Medtronic, Min-
neapolis, MN, USA) was used in seven patients and a Cos-
grove–Edwards ring (Edwards Life Sciences, Irvine, CA, 
USA) in 45 patients. With regard to the size of the ring, a 
33-mm Duran ring or #30-mm Cosgrove ring was used for 
male patients, while a #31-mm Duran ring or #28-mm Cos-
grove ring was used for female patients. Procedures other 
than ring annuloplasty, such as edge-to-edge repair, were 
not performed for the tricuspid valve.
Fig. 1  A flow diagram of patients in the study. pts patients, TR tri-
cuspid regurgitation, TAD tricuspid annular diameter, MV mitral 
valve, f/u follow-up, TV tricuspid valve, TVR tricuspid valve repair
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Echocardiographic measurements
Preoperative transthoracic echocardiography, including 
two-dimensional echocardiographic and Doppler color 
flow examinations, was performed in all of the patients 
by the same experienced operator (M.H.) during the week 
before surgery.
TR was assessed by Doppler color flow mapping images 
of the regurgitant jet and pulsed wave Doppler evidence of 
systolic flow reversal in the inferior vena cava or hepatic 
veins. The view with maximal spatial distribution of the 
regurgitant jet was selected, and the jet and right atrial 
areas were measured in the same frame by planimetry. 
The severity of TR was graded as follows: none (grade 0), 
no regurgitant jet; mild (grade 1+), a jet area of <20 % 
of the right atrial area; moderate (grade 2+), a jet area of 
20–33 % of the right atrial area; and severe (grade 3+), a 
jet area of >33 % of the right atrial area [3, 13, 14]. Patients 
Table 1  The baseline characteristics of the patients
The data are shown as the mean ± standard deviation or number (frequency)
BSA body surface area, MV mitral valve, TR tricuspid regurgitation, LAD left atrial dimension, LVDd left ventricular diastolic dimension, LVDs 
left ventricular systolic dimension, LVEF left ventricular ejection fraction, TAD tricuspid annular diameter
Operative period characteristics All (n = 125) Early period (1987–1997, n = 54) Late period (1998–2006 n = 71) P value
Age (years) 58.0 ± 12.0 53.4 ± 11.7 61.5 ± 11.1 <0.001
Age > 50 years 103 (82.4 %) 40 (74.1 %) 63 (88.7 %) 0.06
Male sex 54 (43.2 %) 25 (46.3 %) 29 (40.8 %) 0.59
BSA (m2) 1.53 ± 0.17 1.50 ± 0.15 1.55 ± 0.17 0.15
BSA ≥1.50 m2 61 (48.8 %) 19 (35.2 %) 42 (59.2 %) 0.008
Rheumatic disease 69 (55.2 %) 39 (72.2 %) 30 (42.3 %) 0.001
Mitral stenosis dominant 56 (44.8 %) 34 (63.0 %) 22 (31.0 %) 0.001
Acute onset of MV disease (<1 month) 10 (8.0 %) 3 (5.6 %) 7 (9.9 %) 0.512
Concomitant aortic valve surgery 44 (35.2 %) 19 (35.2 %) 25 (35.2 %) 1.0
Redo surgery 20 (16.0 %) 11 (20.4 %) 9 (12.7 %) 0.25
Pulmonary hypertension 63 (50.4 %) 36 (66.7 %) 27 (38.0 %) 0.002
Atrial fibrillation 70 (56.0 %) 38 (70.4 %) 32 (45.1 %) 0.005
MV repair 11 (8.8 %) 1 (1.9 %) 10 (14.1 %) 0.02
Maze procedure 6 (4.8 %) 1 (1.9 %) 5 (7.0 %) 0.23
Preoperative TR 0:1+:2+ 5:82:38 4:37:13 1:45:25 0.13
TAD (mm) 36.5 ± 5.2 36.0 ± 6.1 36.9 ± 4.3 0.34
TAD ≥35 mm 89 (71.2 %) 32 (59.3 %) 57 (80.3 %) 0.01
Indexed TAD (mm/m2) 24.1 ± 3.8 24.1 ± 4.5 24.1 ± 3.2 0.91
Indexed TAD ≥21 mm/m2 95 (76.0 %) 36 (66.7 %) 59 (83.1 %) 0.03
LAD (mm) 55.7 ± 10.4 57.0 ± 10.0 54.6 ± 10.6 0.21
LAD ≥60 mm 45 (36.0 %) 22 (40.7 %) 23 (32.4 %) 0.34
Indexed LAD (mm/m2) 36.8 ± 7.7 38.3 ± 7.8 35.7 ± 7.5 0.06
Indexed LAD ≥35 mm/m2 72 (57.6 %) 36 (66.7 %) 36 (50.7 %) 0.07
LVDd (mm) 55.1 ± 9.1 54.0 ± 10.3 56.0 ± 8.1 0.23
LVDd ≥55 mm 62 (49.6 %) 24 (44.4 %) 38 (49.6 %) 0.32
Indexed LVDd (mm/m2) 36.3 ± 6.1 36.1 ± 7.0 36.4 ± 5.3 0.79
Indexed LVDd ≥35 mm/m2 63 (50.4 %) 25 (46.3 %) 38 (53.5 %) 0.42
LVDs (mm) 36.2 ± 7.3 36.2 ± 7.9 36.3 ± 6.9 0.93
LVDs ≥40 mm 39 (31.2 %) 20 (37.0 %) 19 (26.8 %) 0.22
Indexed LVDs (mm/m2) 23.9 ± 5.0 24.2 ± 5.2 23.7 ± 4.9 0.60
Indexed LVDs ≥25 mm/m2 44 (35.2 %) 23 (42.6 %) 21 (29.6 %) 0.13
LVEF 0.66 ± 0.08 0.66 ± 0.08 0.66 ± 0.09 0.91
LVEF <0.65 50 (40.0 %) 24 (44.4 %) 26 (36.6 %) 0.376
Tricuspid valve repair 52 (41.6 %) 0 (0 %) 52 (73.2 %) <0.001
Follow-up period (years) 12.2 ± 6.0 16.0 ± 6.7 9.5 ± 3.3 <0.001
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with severe preoperative TR were excluded from the study. 
If the estimated ratio of the jet area to the right atrial area 
was close to a cutoff point, the grade of jet eccentricity was 
increased to the next higher value. Systolic flow reversal in 
the inferior vena cava or hepatic veins on pulsed wave Dop-
pler images was considered to indicate at least moderate 
TR, regardless of the other findings [3, 14].
In addition to valvular examinations and routine meas-
urements (e.g., left ventricular and left atrial dimensions), 
the TAD was measured in the apical four-chamber view in 
late diastole at the time of maximal tricuspid valve open-
ing, as recommended by Foale et al. [15] (Fig. 2).
Postoperative transthoracic echocardiography was per-
formed before discharge and every year thereafter.
Follow‑up
All of the patients were followed up at the Osaka General 
Medical Center at 3, 6, and 12 months postoperatively. 
After 1 year, most patients (>90 %) were followed up at 3- 
or 6-month intervals at the Osaka General Medical Center; 
the other patients were followed up by local cardiologists. 
Most patients underwent echocardiography, which was 
performed by the same experienced operator (M.H.), each 
year at the Osaka General Medical Center. With the excep-
tion of five patients who were lost to follow-up at >5 years 
after surgery, follow-up is ongoing for all of the surviving 
patients.
The follow-up for severe TR was censored when the 
patient died without severe postoperative TR. Although 
there were three patients whose TR diminished from 
severe (grade 3+) to moderate (grade 2+), probably due 
to enhanced medication, the follow-up of their TR was dis-
continued when severe TR was first observed.
Statistical analysis
Continuous and categorical variables are reported as the 
mean and standard deviations (SD), and as frequencies 
with percentages, respectively. Continuous variables were 
compared using Student’s t test. Categorical variables were 
compared using Fisher’s exact test if any cell had a count 
of less than 5 in a contingency table; otherwise, the Chi-
squared test was used. Curves for survival and freedom 
from severe TR were estimated using the Kaplan–Meier 
method and compared using the log-rank test. A univari-
ate analysis using a log-rank test was used to identify the 
risk factors for severe TR. A multivariate analysis, which 
included the risk factors with P values of <0.2 in the uni-
variate analysis, was adjusted using the Cox proportional 
hazard regression model with variable selection (such as 
forward, backward, and stepwise selection). Hazard ratios 
and 95 % confidence intervals (CIs) were estimated using 
the Cox proportional hazard regression model. Changes 
in the TAD from the preoperative period to the postopera-
tive period were compared between groups by a two-way 
repeated-measures analysis of variance (ANOVA) that 
included the main effects of the group and time and the 
interaction effect between them.
All of the significance tests were two sided and P values 
of <0.05 were considered to indicate statistical significance. 
All of the statistical analyses were performed using the 
SPSS 21.0 software program (IBM, Armonk, NY, USA).
Results
Survival
The follow-up period ranged from 1.0 to 24.7 years (mean 
12.3 years; median 11.7 years). Late death occurred in 38 
patients at 1–23 years after surgery. The causes of death 
included heart failure (n = 8), malignancy (n = 6), septice-
mia (n = 4), cerebral bleeding (n = 3), pneumonia (n = 3), 
renal failure (n = 2), cerebral infarction (n = 1), and bowel 
necrosis (n = 1); the cause of death was unknown in 10 
patients. Six of the 8 patients who died of heart failure had 
severe TR at the time of death. Five patients were lost to 
follow-up at 5–18 years.postoperatively. The survival rates 
at postoperative years 5, 10, 15, and 20 were 91, 81, 64, 
and 59 %, respectively. The survival of the patients in the 
early and late periods did not differ to a statistically signifi-
cant extent (P = 0.90).
The rate of postoperative freedom from severe TR 
in the earl‑period patients
Nineteen of the 54 early-period patients (none of whom 
underwent TVR) developed severe postoperative TR. The 
Fig. 2  The measurement of the tricuspid annular diameter
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rates of freedom from severe TR at postoperative years 
5, 10, 15, and 20 were 83, 76, 63, and 59 %, respectively 
(Fig. 3). Three patients in the early period underwent TVR 
during the follow-up period. All of these three patients 
underwent aortic valve replacement and tricuspid valve 
annuloplasty (two for severe TR and one for moderate TR). 
One of these patients died of septicemia during the periop-
erative period.
The risk factors for severe postoperative TR in the 
early‑period patients
A univariate analysis showed that preoperative moder-
ate (grade 2+) TR, atrial fibrillation, an indexed left atrial 
diameter of ≥35 mm/m2, and ≥50 years of age were sig-
nificantly associated with severe postoperative TR (all 
P < 0.05, log-rank test) (Table 2). Seven variables, includ-
ing a dominant lesion of mitral stenosis, a body surface 
area of ≥1.50 m2, and a left ventricular systolic dimen-
sion of ≥40 mm, in addition to the four significant vari-
ables listed above, showed a P value of <0.2. These fac-
tors were entered into a multivariate analysis using the Cox 
proportional-hazards model with variable selection meth-
ods (forward, backward, and stepwise methods). All of the 
methods provided the same result: preoperative moderate 
(grade 2+) TR was a significant risk factor for severe post-
operative TR (Table 2). The rates for freedom from severe 
TR at postoperative years 5, 10, and 15 were 59, 47, and 
24 %, respectively, for the 13 patients with grade 2+ TR, 
and 90, 84, and 74 %, respectively, for the 41 patients with 
grade ≤1+ TR (Fig. 4).
Freedom from severe TR in the late‑period patients
Four of the late-period patients developed severe TR. The 
rates for freedom from severe TR at postoperative years 
5, 10, and 15 were 96, 93, and 93 %, respectively (Fig. 1). 
The rate of freedom from severe TR in the late-period 
patients was significantly higher than that in the early-
period patients (P = 0.004). One patient in the late period 
underwent TVR with a prosthetic ring during the follow-up 
period for severe TR.
Table 3 shows the characteristics of the 52 patients who 
underwent TVR and the 19 patients who did not in the 
late period. Besides a larger TAD, the patients who under-
went TVR had a greater number of potential risk factors 
for severe postoperative TR (such as grade 2+ TR, atrial 
fibrillation, and a greater left atrial dimension) in the early 
period than the patients who did not undergo TVR. None-
theless, none of the patients who underwent TVR devel-
oped severe postoperative TR. In contrast, four of the 19 
patients who did not undergo TVR developed severe post-
operative TR. The rates of freedom from severe TR at 5 and 
10 years were 100 and 100 %, respectively, in the patients 
who underwent TVR, and 83 and 77 %, respectively, in 
the patients who did not undergo TVR (P = 0.001, Fig. 5). 
Table 4 shows the characteristics of each of the four 
patients who developed severe TR in the late period. The 
TAD ranged from 27 to 35 mm, and all four patients had 
a TAD of ≤35 mm. Similarly, the indexed TAD ranged 
from 17.9 to 22.2 mm, and three of the four patients had an 
indexed TAD of <21 mm/m2.
Serial changes in the TAD
Because the preoperative and postoperative TAD values 
were serially measured in most patients, the preoperative 
and postoperative indexed TAD values were compared 
among three groups of patients, who were categorized as 
follows. Group 1 included patients who did not undergo 
TVR and who did not develop severe postoperative TR 
(n = 39; early period, n = 24; late period, n = 15). Group 
2 included patients who did not undergo TVR and who 
developed severe postoperative TR (n = 18; early period, 
n = 14; late period n = 4). Group 3 included patients who 
underwent TVR (none of them developed severe postopera-
tive TR) (n = 51, all in the late period). Seventeen patients 
in whom the postoperative TAD was not serially measured 
were excluded from this analysis. In groups 1 and 3, the 
value that was used for the postoperative TAD was obtained 
at the last follow-up examination (group 1: postoperative 
Fig. 3  Freedom from severe TR in patients of the early and late peri-
ods. TR tricuspid regurgitation. P = 0.004 (log-rank test)
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year, 13.7 ± 6.0; group 3: postoperative year, 8.2 ± 3.6). In 
group 2, the value that was used for the postoperative TAD 
was obtained at the time of the diagnosis of severe postop-
erative TR (postoperative year, 9.0 ± 6.2).
The changes in the indexed TAD values before and after 
surgery differed among the groups (P < 0.001 for an interac-
tion effect between group and time in a two-way repeated-
measures ANOVA). Specifically, the preoperative indexed 
TAD values of the patients in group 3 were larger than those in 
groups 1 and 2 because TVR was performed in patients with 
a large TAD. The indexed TAD was increased after surgery in 
groups 1 and 2, but was decreased after surgery in group 3. 
The postoperative indexed TAD values of the patients in group 
2 were larger than those in groups 1 and 3 (Fig. 6).
Discussion
The findings of the present study were as follows. First, a 
relatively high rate of patients without severe preoperative 
TR developed severe TR after mitral valve surgery if the 
tricuspid valve was left untouched. Additionally, moder-
ate preoperative TR was the most significant risk factor for 
severe postoperative TR. Second, the aggressive application 
of TVR using a prosthetic ring prevented the development 
of severe postoperative TR for a long period of time. Third, 
our indication, tricuspid annular dilatation as measured by 
a preoperative echocardiogram, might not be a good indi-
cator of whether patients undergoing mitral valve surgery 
should undergo concomitant TVR.
Table 2  The univariate and multivariate analysis of risk factors for severe TR after mitral valve surgery in the early-period patients (1987–1997)
TR tricuspid regurgitation, HR hazard ratio, BSA body surface area, MV mitral valve, LAD left atrial dimension, LVDd left ventricular diastolic 
dimension, LVDs left ventricular systolic dimension, LVEF left ventricular ejection fraction, TAD tricuspid annular diameter, CI confidence 
interval, NE not estimable
a The HRs and 95 % CIs were estimated using the Cox proportional-hazards model
b The numbers of patients with an acute onset of MV disease (<1 month), MV repair, and the maze procedure were small. Thus, the parameters 
of these factors were not estimable
c The P values were based on the log-rank test
Factors Number  
(frequency, %)
Univariate analysis Multivariate analysis




Age >50 years 40 (74.1) 4.28 (0.99–8.5) 0.034
Male sex 25 (46.3) 0.71 (0.29–1.75) 0.457
BSA ≥1.50 m2 19 (35.2) 0.50 (0.18–1.39) 0.175
Rheumatic disease 39 (72.2) 2.15 (0.63–7.37) 0.210
Mitral stenosis dominant 34 (63.0) 2.27 (0.65–6.79) 0.133
Acute onset of MV disease (<1 month) 3 (5.6) NEb 0.263
Concomitant aortic valve surgery 19 (35.2) 1.72 (0.69–4.26) 0.236
Redo surgery 11 (20.4) 0.89 (0.30–2.68) 0.841
Pulmonary hypertension 36 (66.7) 1.42 (0.54–3.73) 0.469
Atrial fibrillation 38 (70.4) 4.91 (1.14–21.21) 0.018 3.97 (0.90–17.5) 0.068
MV repair 1 (1.9) NEb 0.495
Maze procedure 1 (1.9) NEb 0.495
Moderate (2+) TR 13 (24.1) 3.89 (1.54–9.84) 0.002 3.08 (1.21–7.82) 0.018
TAD ≥35 mm 32 (59.3) 1.39 (0.57–3.42) 0.470
Indexed TAD ≥21 mm/m2 36 (66.7) 1.48 (0.57–3.86) 0.424
LAD ≥60 mm 22 (40.7) 1.66 (0.69–4.02) 0.253
Indexed LAD ≥35 mm/m2 36 (66.7) 3.87 (1.13–13.26) 0.020
LVDd ≥55 mm 24 (44.4) 0.59 (0.24–1.49) 0.262
Indexed LVDd ≥35 mm/m2 25 (46.3) 0.92 (0.38–2.23) 0.854
LVDs ≥40 mm 20 (37.0) 0.52 (0.19–1.43) 0.197
Indexed LVDs ≥25 mm/m2 23 (42.6) 1.20 (0.50–2.89) 0.691
LVEF <0.65 24 (44.4) 0.91 (0.37–2.24) 0.843
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The prevalence and predictors of significant 
postoperative TR after mitral valve surgery
Significant TR has previously been reported to develop at 
a relatively high number of cases after mitral valve surgery 
[3, 5, 8, 9, 16, 17]. The risk factors for postoperative TR in 
these studies included older age [3, 17], the grade of preop-
erative TR [8, 17], atrial fibrillation [8, 9, 16], a huge left 
atrium [8, 9], a long time from the onset of mitral valve 
disease to surgery [9], rheumatic changes of the tricus-
pid valve [9], and a low ejection fraction [16]. In the pre-
sent study, the rate of severe postoperative TR at 20 years 
among the early-period patients (none of whom underwent 
TVR) was 41 %. The univariate analysis revealed that the 
predictors of severe TR were moderate preoperative TR, 
a large left atrial dimension, atrial fibrillation, and older 
age. Our results are therefore similar to those of previous 
studies.
The effectiveness of tricuspid valve repair with a 
prosthetic ring for less than severe TR in patients who 
underwent mitral valve surgery
In the late period of this study, we aggressively applied 
TVR using a prosthetic ring in 52 of the 71 patients who 
underwent mitral valve surgery. Although our indication 
for TVR was tricuspid annular dilatation (TAD ≥35 mm), 
these patients also had other risk factors, such as moderate 
TR, atrial fibrillation, rheumatic disease, pulmonary hyper-
tension, and a large left atrium (Table 3). Nonetheless, the 
rate of freedom from severe TR was 100 % at 15 years. 
Thus, prophylactic TVR using a prosthetic ring appears to 
be effective in preventing the development of severe post-
operative TR in patients without severe preoperative TR.
The validity of tricuspid annular dilatation as an 
indication for TVR
In the present study, we attempted to examine the validity 
of our indication (preoperative tricuspid annular dilata-
tion) for prophylactic TVR in patients undergoing mitral 
valve surgery. In the early-period patients (none of whom 
underwent TVR), tricuspid annular dilatation (a TAD 
of ≥35 mm or an indexed TAD of ≥21 mm/m2) was not a 
risk factor for severe postoperative TR (Table 2). The log-
rank test did not show a significant difference in the rate 
of freedom from severe postoperative TR between patients 
with large and small TAD values (Fig. 7a, b). Furthermore, 
in the late-period patients in whom tricuspid annular dilata-
tion (TAD ≥35 mm) was used as an indicator for TVR, the 
cumulative incidence of severe TR at 10 years in patients 
who did not undergo tricuspid repair was 23 %. We are 
therefore of the opinion that tricuspid annular dilatation 
might not be a valid indicator of whether patients undergo-
ing mitral valve surgery should undergo concomitant TVR. 
This conclusion may be surprising because many surgeons 
believe that tricuspid annular dilatation is an indicator of 
TVR in patients undergoing mitral valve surgery, because 
the guidelines for the management of valvular heart disease 
suggest that the performance of TVR in such patients.
Tricuspid annular dilatation, as measured by preopera-
tive or intraoperative echocardiography, has been recom-
mended as an indication for TVR by several authors [13, 
18, 19] based on the observation that the TAD was corre-
lated with the severity of TR. Following this recommen-
dation, tricuspid annular dilatation was used as an indica-
tion for TVR at the time of mitral valve surgery by Tager 
et al. [20] (TAD ≥30 mm), Colombo et al. [21] (indexed 
TAD ≥21 mm/m2), Van de Veire et al. [22] (TAD ≥40 mm), 
and Calafiore et al. [23] (systolic TAD ≥24 mm). Drey-
fus et al. [6] performed TVR in patients with a TAD 
of ≥70 mm, which was measured intraoperatively from 
the anteroseptal to the anteroposterior commissures in 
the arrested heart. These authors concluded that tricuspid 
annular dilatation was an appropriate indicator of whether 
patients undergoing mitral valve surgery should undergo 
concomitant TVR. However, a detailed examination of the 
data from the above-mentioned studies might not fully sup-
port this conclusion. In the study by Dreyfus et al. [6], 55 
Fig. 4  Freedom from severe TR in the early-period patients with 
grade 2+ and ≤1+ TR. The rate of freedom from severe TR in 
patients with grade 2+ TR was significantly lower than that in 
patients with grade ≤1+ TR (P = 0.002; log-rank test). TR tricuspid 
regurgitation
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out of 163 patients with a TAD of <70 mm developed grade 
3+ to 4+ TR at a mean follow-up time of 4.8 years. More-
over, the follow-up period in some of the studies appears to 
be insufficient [22, 23].
In contrast, other studies have reported that preoperative 
tricuspid annular dilatation is not a pivotal factor for the pro-
gression of TR after mitral valve surgery [24, 25]. Goldstone 
et al. [17] recently reported that older age and the grade of 
preoperative TR were independent predictors of the postop-
erative progression of TR in patients undergoing mitral valve 
repair for mitral valve prolapse with TR that was assessed 
as being less than severe. However, they reported that when 
limited to patients with mild TR (or those without TR), the 
indexed TAD was the only significant risk factor.
We also analyzed the risk factors of 41 patients in the 
early period with mild or none (grade 1+ or 0) preopera-
tive TR. We found that atrial fibrillation and a huge left 
atrium (left atrial dimension ≥35 mm) were significant 
risk factors for severe postoperative TR, but that tricuspid 
annular dilatation (a TAD of ≥35 mm or an indexed TAD 
of ≥21 mm/m2) was not a risk factor in a univariate analy-
sis (log-rank test). Because of the small number of patients, 
our study does not have sufficient statistical power to prove 
that tricuspid annular dilatation is not a valid indicator of 
tricuspid valve surgery. We believe that the validity of tri-
cuspid annular dilatation as an indicator of whether patients 
should undergo TVR needs to be re-evaluated.
The mechanisms underlying secondary TR after mitral 
valve surgery
An understanding of the mechanisms underlying secondary 
TR is improving based on the results of the detailed analy-
sis of the structure of the tricuspid valve. Tricuspid annu-
lar dilatation is commonly observed in patients with severe 
TR [14, 26–28]. We also showed that the TAD was signifi-
cantly increased in patients who developed severe postop-
erative TR at the time of its development (Fig. 6).
Table 3  The characteristics of patients who did underwent TVR in the late period and those who did not undergo TVR
TVR tricuspid valve repair, BSA body surface area, MV mitral valve, LAD left atrial dimension, LVDd left ventricular diastolic dimension, LVDs 
left ventricular systolic dimension, LVEF left ventricular ejection fraction, TAD tricuspid annular diameter
Characteristics Underwent TVR (n = 52) Did not undergo TVR (n = 19) P value
Age (years) 61.9 ± 9.5 60.3 ± 14.8 0.59
Male sex 19 (36.5 %) 10 (52.6 %) 0.22
Age >50 years 48 (92.3 %) 15 (78.9 %) 0.12
BSA (m2) 1.55 ± 0.18 1.52 ± 0.16 0.45
Rheumatic disease 28 (53.8 %) 2 (10.5 %) 0.001
Mitral stenosis dominant 21 (40.4 %) 1 (5.3 %) 0.004
Acute onset of MV disease (<1 month) 3 (5.8 %) 4 (21.1 %) 0.08
Concomitant aortic valve surgery 18 (34.6 %) 7 (36.8 %) 0.87
Redo surgery 8 (15.4 %) 1 (5.3 %) 0.43
Pulmonary hypertension 25 (48.1 %) 2 (10.5 %) 0.005
Atrial fibrillation 30 (57.7 %) 2 (10.5 %) <0.001
MV repair 4 (7.7 %) 6 (31.6 %) 0.01
Maze procedure 5 (9.6 %) 0 (0 %) 0.32
Preoperative TR 0:1+:2+ 0:27:25 1:18:0 <0.001
TAD (mm) 38.5 ± 3.0 32.5 ± 4.3 <0.001
TAD ≥35 mm 51 (98.1 %) 6 (31.6 %) <0.001
Indexed TAD (mm/m2) 25.0 ± 2.8 21.5 ± 2.9 <0.001
Indexed TAD ≥21 mm/m2 49 (94.2 %) 10 (52.6 %) <0.001
LAD (mm) 56.9 ± 9.6 48.4 ± 10.8 0.002
LAD ≥60 mm 21 (40.4 %) 2 (10.5 %) 0.022
Indexed LAD (mm/m2) 37.1 ± 7.2 32.0 ± 7.1 0.011
Indexed LAD >35 mm/m2 30 (57.7 %) 6 (31.6 %) 0.05
LVDd (mm) 55.5 ± 8.9 57.2 ± 5.4 0.43
Indexed LVDd (mm/m2) 35.9 ± 5.5 37.9 ± 4.7 0.15
LVDs (mm) 36.2 ± 7.3 36.4 ± 5.7 0.91
Indexed LVDs (mm/m2) 23.5 ± 5.1 24.2 ± 4.5 0.61
LVEF 0.65 ± 0.08 0.69 ± 0.10 0.13
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In addition, the tethering of the tricuspid valve leaflets 
may play a major role in the development of secondary TR. 
Right ventricular enlargement due to mitral valve disease 
causes tricuspid annular dilatation and the displacement of 
the papillary muscles, leading to the tethering of the tricus-
pid valve leaflets. This results in inadequate leaflet coapta-
tion [29, 30]. A recent study used three-dimensional echo-
cardiography to evaluate patients with secondary TR and 
reported that the tricuspid annulus was not only dilated, but 
also flattened and circular in patients with secondary TR 
[31].
However, the reason why these changes in the tri-
cuspid valve structure occur after mitral valve surgery 
is not clear. In the present study, we excluded patients 
with recurrence or in which the mitral valve lesions were 
insufficiently repaired and those who developed abnor-
mal prosthetic valve function [32]. Thus, the tricus-
pid valve was unlikely to have been affected by resid-
ual mitral valve disease. The tricuspid valve was also 
unlikely to have been affected by persistent pulmonary 
hypertension after mitral valve surgery. This hypothesis 
is based on our finding that postoperative pulmonary 
hypertension, as assessed by follow-up echocardiog-
raphy, was not a significant risk factor for severe post-
operative TR in our univariate analysis [P = 0.39 (log-
rank test); hazard ratio = 1.48, P = 0.40 (Cox hazards 
model)]. Previous studies [1, 6] have also reported simi-
lar findings.
Fig. 5  Freedom from severe TR in the late-period patients who 
underwent TVR and those who did not undergo TVR. None of the 
patients who underwent TVR developed severe TR. TR tricuspid 
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Some authors have hypothesized that tricuspid annular 
dilatation may be an ongoing disease process that contin-
ues even after the mitral valve lesion has been repaired 
[6]. This hypothesis may explain the findings of previous 
studies, which noted that the incidence of postoperative TR 
was higher in patients with rheumatic mitral disease than 
Fig. 6  Changes in the indexed tricuspid annular diameter before and 
after surgery. Group 1 consisted of 39 patients who did not undergo 
TVR and who did not develop severe postoperative TR. Group 2 
consisted of 18 patients who did not undergo tricuspid valve sur-
gery and who developed severe postoperative TR. Group 3 consisted 
of 51 patients who underwent TVR (none of them developed severe 
postoperative TR). Closed circles indicate the early-period patients; 
open circles indicate the late-period patients. Open squares and bars 
indicate the means and standard deviations for each group of patients. 
A two-way repeated ANOVA showed that the P values for the main 
effects of group and time were P = 0.03 and P < 0.001, respec-
tively; while the P value for the interaction effect between them was 
P < 0.001. See the text for more information about the comparisons 
between the groups. BSA body surface area, TR tricuspid regurgita-
tion, TVR tricuspid valve repair, TAD tricuspid annular diameter
Fig. 7  Freedom from severe TR in the early-period patients accord-
ing to the tricuspid annular diameter. The log-rank test did not show 
a significant difference between 32 patients with a TAD of ≥35 mm 
and 22 patients with a TAD of <35 mm (a). Furthermore, there was 
no difference between 36 patients with an indexed TAD of ≥21 mm/
m2 and 18 patients with an indexed TAD of <21 mm/m2 (b). TR tri-
cuspid regurgitation, BSA body surface area, TAD tricuspid annular 
diameter
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in those with degenerative mitral disease [24]. Additionally, 
a long time from the onset of mitral valve disease to sur-
gery is a predictor of late TR after mitral valve surgery [9]. 
However, the hypothesis that tricuspid annular dilatation is 
an ongoing process is speculative and should be the subject 
of further studies.
Study limitations
The present study is associated with several limitations. 
First, this study was a retrospective analysis with a small 
sample size. Although our policy of tricuspid valve sur-
gery was consistent during the study period, many surgeons 
were involved over a relatively long study period. A pro-
spective study with a large number of patients would help 
to determine the risk factors for postoperative TR, as well 
as the importance of tricuspid annular dilatation. Second, 
over half of the patients had rheumatic heart disease, and 
the mitral valve was replaced in almost all of the patients. 
Although we accounted for these factors (e.g., rheumatic 
disease, mitral valve repair, the acute onset of mitral valve 
disease) in the analysis, our results may not be applicable 
to patients who undergo mitral valve repair for degenerative 
disease. Third, the severity of TR was mainly determined 
by comparing the regurgitant jet area with the right atrial 
area, rather than by the recommendations of the American 
Society of Echocardiography [33]. This is because most of 
the patients in this study underwent surgery before the rec-
ommendation had been reported. Finally, we did not evalu-
ate the tethering of the tricuspid valve leaflets, the dimen-
sions and functions of the right ventricle and atrium, or 
the shape of the tricuspid annulus. These details of the tri-
cuspid valve complex should be further evaluated because 
they may help to predict secondary TR after mitral valve 
surgery.
Conclusions
Relatively high rates of patients without severe preopera-
tive TR develop severe postoperative TR if the tricuspid 
valve is left untouched at the time of mitral valve surgery. 
Moderate preoperative TR is the most significant risk fac-
tor for severe postoperative TR. The aggressive application 
of TVR using a prosthetic ring may prevent the develop-
ment of severe postoperative TR. The measurement of tri-
cuspid annular dilatation by preoperative echocardiography 
might not be a good indicator of whether patients under-
going mitral valve surgery should undergo concomitant 
TVR. However, further study will be needed to confirm our 
results.
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